Patents Assigned to Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
  • Publication number: 20230227322
    Abstract: A method for preparing lanthanum carbonate tetrahydrate and a product thereof. The lanthanum carbonate tetrahydrate is prepared by reacting lanthanum oxide and acetic acid with potassium carbonate or potassium bicarbonate or ammonium bicarbonate to prepare lanthanum carbonate octahydrate, and drying the lanthanum carbonate octahydrate. Compared with the lanthanum carbonate tetrahydrate in the prior art, the prepared lanthanum carbonate tetrahydrate has a characteristic spectral peak on a terahertz spectrum, and has excellent dissociation and dissolution characteristics of lanthanum ions.
    Type: Application
    Filed: August 28, 2020
    Publication date: July 20, 2023
    Applicant: NANJING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD.
    Inventor: Yongxiang XU
  • Publication number: 20150284359
    Abstract: The present invention discloses methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2,6-dioxopiperidine and intermediates thereof, namely, the synthesis of compounds of the Formula (I), with each substitutional group defined in the patent specification. Owing to the advantages of high productivity, little influence to the environment and material accessibility, the methods of the present invention is suitable for industrial production.
    Type: Application
    Filed: June 15, 2015
    Publication date: October 8, 2015
    Applicants: Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
    Inventors: Rong Yan, Hao Yang, Yongxiang Xu
  • Publication number: 20150284329
    Abstract: The present invention discloses methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2,6-dioxopiperidine and intermediates thereof, namely, the synthesis of compounds of the Formula (I), with each substitutional group defined in the patent specification. Owing to the advantages of high productivity, little influence to the environment and material accessibility, the methods of the present invention is suitable for industrial production.
    Type: Application
    Filed: June 15, 2015
    Publication date: October 8, 2015
    Applicants: Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
    Inventors: Rong Yan, Hao Yang, Yongxiang Xu
  • Patent number: 9101620
    Abstract: The present invention provides polymorph of 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindole-2-yl)-piperidine-2,6-dione, and also the preparing methods and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: August 11, 2015
    Assignee: Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
    Inventors: Rong Yan, Hao Yang, Yongxiang Xu
  • Patent number: 9085530
    Abstract: The present invention discloses methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2,6-dioxopiperidine and intermediates thereof, namely, the synthesis of compounds of the Formula (I), with each substitutional group defined in the patent specification. Owing to the advantages of high productivity, little influence to the environment and material accessibility, the methods of the present invention is suitable for industrial production.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: July 21, 2015
    Assignees: Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
    Inventors: Rong Yan, Hao Yang, Yongxiang Xu
  • Patent number: 8586592
    Abstract: The present invention provides a pharmaceutical formulation comprising voriconazole or a pharmaceutically acceptable derivative thereof, and an excipient of formula (I), i.e., monomethoxy poly(ethylene glycol)-poly (D,L-lactic acid) block copolymers (mPEG-PDLLA). The pharmaceutical formulation of the present invention has been shown to be stable and safe by experiments.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: November 19, 2013
    Assignees: Nanjing Cavendish Bio-Engineering Technology Co., Ltd., Yongxiang Yu
    Inventor: Yongxiang Xu
  • Publication number: 20130018181
    Abstract: The present invention provides a novel and highly stereoselective process for preparing gemcitabine, which is suitable for industrial production, wherein, it includes the following reactions. Additionally, the invention discloses the key intermediates. The definition for the groups of G1, G2, G3, G4, and G5 are described in the specification.
    Type: Application
    Filed: September 18, 2012
    Publication date: January 17, 2013
    Applicant: Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
    Inventors: Yongxiang XU, Hao YANG, Wen HOU
  • Patent number: 8324373
    Abstract: The present invention provides a novel and highly stereoselective process for preparing gemcitabine, which is suitable for industrial production, wherein, it includes the following reactions. Additionally, the invention discloses the key intermediates. The definition for the groups of G1, G2, G3, G4, and G5 are described in the specification.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: December 4, 2012
    Assignee: Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
    Inventors: Yongxiang Xu, Hao Yang, Wen Hou
  • Publication number: 20120077982
    Abstract: The present invention discloses methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2,6-dioxopiperidine and intermediates thereof, namely, the synthesis of compounds of the Formula (I), with each substitutional group defined in the patent specification. Owing to the advantages of high productivity, little influence to the environment and material accessibility, the methods of the present invention is suitable for industrial production.
    Type: Application
    Filed: June 1, 2010
    Publication date: March 29, 2012
    Applicants: NANJING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD.
    Inventors: Rong Yan, Hao Yang, Yongxiang Xu
  • Publication number: 20110257197
    Abstract: The present invention provides a pharmaceutical formulation comprising voriconazole or a pharmaceutically acceptable derivative thereof, and an excipient of formula (I), i.e., monomethoxy poly(ethylene glycol)-poly (D,L-lactic acid) block copolymers (mPEG-PDLLA). The pharmaceutical formulation of the present invention has been shown to be stable and safe by experiments.
    Type: Application
    Filed: December 31, 2009
    Publication date: October 20, 2011
    Applicant: Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
    Inventor: Yongxiang Xu